文献速递淋巴瘤

2000至2013年确诊的结外NK/T细胞淋巴瘤患者的治疗与结局:日本一项协作研究

Treatments and Outcomes of Patients With Extranodal Natural Killer/T-Cell Lymphoma Diagnosed Between 2000 and 2013: A Cooperative Study in Japan.
PubMed 文献 · J Clin Oncol · 2016-10-31

该研究回顾性分析了日本31家机构2000至2013年确诊的358例结外NK/T细胞淋巴瘤(鼻型)患者,局限期最常见一线治疗为放疗联合地塞米松、依托泊苷、异环磷酰胺和卡铂(RT-DeVIC)(66%),进展期最常见为含L-天冬酰胺酶化疗(30%);中位随访5.8年,局限期与进展期5年总生存率分别为68%和24%。

要点

  • 局限期ENKL最常见一线治疗为RT-DeVIC(66%),进展期最常见为含L-天冬酰胺酶化疗(30%)。
  • 中位随访5.8年,局限期与进展期ENKL的5年总生存率分别为68%和24%。
  • 临床实践中接受RT-DeVIC的150例患者,中位随访5.6年,5年OS为72%(95%CI 63%~78%),5年PFS为61%(95%CI 52%~69%)。

核心结论

  • 新治疗使大量患者获得良好的总生存,但治疗前可溶性白细胞介素-2受体升高的局限期ENKL仍需改进治疗策略。

研究设计与样本

  • 回顾性分析日本31家机构2000至2013年确诊的358例结外NK/T细胞淋巴瘤(鼻型)患者。

主要发现

  • 患者中位年龄58岁,257例(72%)为局限期。
  • 局限期ENKL最常见一线治疗为RT-DeVIC(66%),进展期最常见为含L-天冬酰胺酶化疗(30%)。
  • 中位随访5.8年,局限期与进展期ENKL的5年总生存率分别为68%和24%。
  • 自然杀伤淋巴瘤预后指数在本研究中得到验证,但仅4%的局限期ENKL患者被归为高危。
  • 临床实践中接受RT-DeVIC的150例患者,中位随访5.6年,5年总生存率为72%(95%CI 63%~78%),5年无进展生存率为61%(95%CI 52%~69%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose To elucidate the management and outcomes of patients with extranodal natural killer/T-cell lymphoma, nasal type (ENKL), who were diagnosed between 2000 and 2013 in Japan. Patients and Methods Data from 358 patients with ENKL diagnosed between 2000 and 2013 from 31 institutes were retrospectively analyzed. Results Patients' median age was 58 years, and 257 (72%) had localized disease. The most common first-line treatment was radiotherapy with dexamethasone, etoposide, ifosfamide, and carboplatin (RT-DeVIC) (66%) for localized ENKL and L-asparaginase-containing chemotherapy (30%) for advanced ENKL. With a median follow-up of 5.8 years, overall survival (OS) rates at 5 years for localized and advanced ENKL were 68% and 24%, respectively. The prognostic index of natural killer lymphoma was validated in our study, although only 4% of patients with localized ENKL were classified as high risk. With a median follow-up of 5.6 years, OS and progression-free survival at 5 years in the 150 patients who received RT-DeVIC in clinical practice were 72% (95% CI, 63% to 78%) and 61% (95% CI, 52% to 69%), respectively. Toxicities of RT-DeVIC were comparable to those in a previous trial. Multivariate analysis in patients with localized ENKL who received RT-DeVIC identified elevated soluble interleukin-2 receptor as an independent predictive factor for worse OS and progression-free survival (adjusted hazard ratios, 2.28 and 2.46; 95% CI, 1.24 to 4.23 and 1.42 to 4.28; P = .008 and .0014, respectively). Conclusion Favorable OS in response to new treatments was demonstrated in a large number of patients. Improved treatment approaches are needed for localized ENKL exhibiting elevated pretreatment soluble interleukin-2 receptor.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Yamaguchi M, Suzuki R, Oguchi M, et al. Treatments and Outcomes of Patients With Extranodal Natural Killer/T-Cell Lymphoma Diagnosed Between 2000 and 2013: A Cooperative Study in Japan. J Clin Oncol. 2016. PMID: 28034070

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。